Biosimilars

touchONCOLOGY joins Professor Guillaume Canaud (Necker–Enfants Malades Hospital, Paris, France), to discuss EPIK-P1, a retrospective chart review study of patients with PIK3CA-related overgrowth spectrum who have received alpelisib as part of a compassionate use programme. Questions 1. Could you tell us a little about PIK3CA-related Overgrowth Spectrum (PROS), the clinical manifestations and prognosis? (00:25-01:11) 2. […]

Honouring the children and adolescents battling cancer September is Childhood Cancer Awareness Month: A time to recognise the children and adolescents affected by cancer at global and European scale. One would expect that it should be “children first” but sadly too often it is “children last”. There are serious inequalities in access to the best […]

Dear friends and colleagues in the SIOP Europe Community, We are all currently facing difficult challenges and stresses, both personal and professional, in the unprecedented circumstances of the COVID-19 pandemic. As we are now several weeks into the pandemic reaching Europe, the impact has been felt in all European countries and there is naturally anxiety […]

According to the multi-stakeholder international FAIR (Fostering Age Inclusive Research) Trials Initiative, teenagers with cancer must no longer be blocked from entering adult clinical trials.   Teenagers with cancer must no longer be blocked from entering adult clinical trials, according to the multi- stakeholder international FAIR (Fostering Age Inclusive Research) Trials Initiative. The FAIR Trials […]

During 2019, SIOP Europe achieved many exciting milestones, as we launched several new activities. I am delighted to share the highlights of this ‘action packed’ year. 1^st SIOP Europe Annual Meeting successfully launched in Prague The first edition of the SIOP Europe Annual Meeting was successfully launched in Prague on 20–24 May. Not only did […]

Childhood cancer care continues to suffer from widespread inequalities, says Pamela Kearns. Inequalities in access to the best available care, expertise and knowledge for children and young people with cancer remains a critical issue across Europe. These inequalities contribute to 20 percent differences in survival rates when comparing North and Western Europe with Central and […]

At the ASCO 2019 annual meeting, Cornelis van Tilburg discusses findings from recent studies investigating the efficacy and safety of larotrectinib in paediatric TRK fusion cancer patients (NCT02637687 and NCT02576431) and what this means for the future. Questions 1.What percentage of paediatric tumours have tropomyosin receptor kinase (TRK) fusions and in what tumour types are […]

Biosimilars, which are copies of patent-expired large-molecule biologic drugs (Table 1),1–8 offer the same rationale as generic drugs. They can give patients, hospitals and healthcare systems the opportunity to expand patient access to care and offer potential budget savings to reinvest (Table 2).1,2,9 They are designed to be similar in effectiveness, safety and quality to […]

Introduction With the growing burden of cancer, sustainable solutions are urgently required to ensure access to effective and safe treatments for all patients.1 Health expenditure on cancer in Europe more than doubled between 1995 and 2014, increasing from €35.7 billion to €83.2 billion;2 high-cost cancer drugs are the main drivers of this increase in many […]